CN104203262A - 芳香族阳离子肽及其用途 - Google Patents

芳香族阳离子肽及其用途 Download PDF

Info

Publication number
CN104203262A
CN104203262A CN201380016624.6A CN201380016624A CN104203262A CN 104203262 A CN104203262 A CN 104203262A CN 201380016624 A CN201380016624 A CN 201380016624A CN 104203262 A CN104203262 A CN 104203262A
Authority
CN
China
Prior art keywords
arg
phe
lys
cytochrome
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380016624.6A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN104203262A publication Critical patent/CN104203262A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
CN201380016624.6A 2012-02-23 2013-02-22 芳香族阳离子肽及其用途 Pending CN104203262A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602418P 2012-02-23 2012-02-23
US61/602,418 2012-02-23
PCT/US2013/027430 WO2013126775A1 (en) 2012-02-23 2013-02-22 Aromatic-cationic peptides and uses of same

Publications (1)

Publication Number Publication Date
CN104203262A true CN104203262A (zh) 2014-12-10

Family

ID=49006261

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380016624.6A Pending CN104203262A (zh) 2012-02-23 2013-02-22 芳香族阳离子肽及其用途

Country Status (7)

Country Link
US (2) US10808008B2 (enExample)
EP (2) EP2817021B1 (enExample)
JP (3) JP2015509504A (enExample)
CN (1) CN104203262A (enExample)
AU (3) AU2013222237B2 (enExample)
CA (1) CA2865409C (enExample)
WO (1) WO2013126775A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
CN107320711A (zh) * 2017-03-24 2017-11-07 南京大学 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用
CN109563131A (zh) * 2016-04-11 2019-04-02 卡诺有限责任公司 手性肽

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN115990242A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9943563B2 (en) 2013-12-02 2018-04-17 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
DE102015207415A1 (de) 2015-04-23 2016-10-27 Adidas Ag Verfahren und Gerät zum Verknüpfen von Bildern in einem Video einer Aktivität einer Person mit einem Ereignis
EP3399990A4 (en) * 2015-12-31 2019-08-14 Scott Duncan THERAPEUTIC COMPOSITIONS WITH PEPTIDES AND USES THEREOF
US12404300B2 (en) 2018-12-18 2025-09-02 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
CN115400201A (zh) * 2021-05-26 2022-11-29 四川大学华西医院 Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
WO2025121297A1 (ja) * 2023-12-08 2025-06-12 サントリーホールディングス株式会社 エネルギー代謝促進用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084606A1 (en) * 2004-01-23 2006-04-20 Szeto Hazel H Methods for reducing oxidative damage
US20090186802A1 (en) * 2005-12-16 2009-07-23 Diatos Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell
US20090221514A1 (en) * 2008-02-26 2009-09-03 Szeto Hazel H Methods for prevention and treatment of acute renal injury
US20120004720A1 (en) * 2004-09-16 2012-01-05 The University Of Alabama G-type peptides and other agents to ameliorate atherosclerosis and other pathologies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2013059071A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084606A1 (en) * 2004-01-23 2006-04-20 Szeto Hazel H Methods for reducing oxidative damage
US20120004720A1 (en) * 2004-09-16 2012-01-05 The University Of Alabama G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
US20090186802A1 (en) * 2005-12-16 2009-07-23 Diatos Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell
US20090221514A1 (en) * 2008-02-26 2009-09-03 Szeto Hazel H Methods for prevention and treatment of acute renal injury

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAZEL H. SZETO: "Cell-permeable, Mitochondrial-targeted,Peptide Antioxidants", 《THE AAPS JOURNAL》 *
M. SORICE等: "Cardiolipin on the surface of apoptotic cells as a possible trigger for anti-phospholipid antibodies", 《CLIN EXP IMMUNOL》 *
SHEY-SHING SHEU 等: "Targeting antioxidants to mitochondria: A new therapeutic direction", 《BBA》 *
STEN ORRENIUS等: "Cardiolipin oxidation sets cytochrome c free", 《NATURE CHEMICAL BIOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563131A (zh) * 2016-04-11 2019-04-02 卡诺有限责任公司 手性肽
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
CN107320711A (zh) * 2017-03-24 2017-11-07 南京大学 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用
WO2018171279A1 (zh) * 2017-03-24 2018-09-27 南京大学 化合物ss-31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用

Also Published As

Publication number Publication date
JP2015509504A (ja) 2015-03-30
HK1204772A1 (en) 2015-12-04
CA2865409A1 (en) 2013-08-29
CA2865409C (en) 2020-07-21
AU2018200000A1 (en) 2018-01-25
EP2817021A4 (en) 2015-09-09
EP2817021B1 (en) 2019-01-02
AU2019232783A1 (en) 2019-10-10
AU2013222237A1 (en) 2014-09-11
EP3513800A1 (en) 2019-07-24
US10808008B2 (en) 2020-10-20
AU2013222237B2 (en) 2017-10-05
WO2013126775A1 (en) 2013-08-29
JP2018076337A (ja) 2018-05-17
JP2020059720A (ja) 2020-04-16
US20210261613A1 (en) 2021-08-26
AU2019232783B2 (en) 2021-07-22
US20150010588A1 (en) 2015-01-08
EP2817021A1 (en) 2014-12-31
EP3513800B1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
AU2019232783B2 (en) Aromatic-cationic peptides and uses of same
JP2016000750A (ja) 芳香族カチオン性ペプチドおよびその使用
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
EP3052115A1 (en) Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
HK1204772B (en) Aromatic-cationic peptides and uses of same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210

RJ01 Rejection of invention patent application after publication